<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720873</url>
  </required_header>
  <id_info>
    <org_study_id>secgolc004</org_study_id>
    <nct_id>NCT03720873</nct_id>
  </id_info>
  <brief_title>EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC</brief_title>
  <official_title>An Multicenter,Phase II Trial of EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm study: EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with
      EGFR-mutant non-small-cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial investigated the efficacy and safety of EGFR-TKIs Combine With Anlotinib as
      First-line Treatment in patients with EGFR-mutant NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>within 6 months of the last visit of last patient, approximately 30 months after inclusion of first patient</time_frame>
    <description>Time from the date of enrolment to discontinuation of treatment for any reason (including progression of disease, treatment toxicity, refusal and death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>through study completion,an average of three years</time_frame>
    <description>Best overall response (complete remission or partial remission) across all assessment time-points according to RECIST Criteria 1.1, during the period from enrolment to termination of trial treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse events graded according to NCI CTCAE V4.03</measure>
    <time_frame>within 6 months of the last visit of last patient, approximately 30 months after inclusion of first patient</time_frame>
    <description>Adverse events graded according to NCI CTCAE V4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Three years</time_frame>
    <description>Defined as the time in month from diagnosis of recurrent NPC to the date of death is observed or to last follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>EGFR Gene Mutation</condition>
  <arm_group>
    <arm_group_label>EGFR-TKIs and Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental:EGFR-TKIs and Anlotinib EGFR-TKIs:erlotinib 150mg QD or gefitinib250mgQD or icotinib 125 mg TID , Anlotinib 12mg po qd d1-14 q21d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib or gefitinib or icotinib</intervention_name>
    <description>Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID</description>
    <arm_group_label>EGFR-TKIs and Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Patients will be treated with Anlotinib 12mg po d1-14 Q21d</description>
    <arm_group_label>EGFR-TKIs and Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Age â‰¥ 18 years

          -  ECOG performance status 0-1

          -  Adequate haematological function, coagulation, liver function and renal function

          -  Pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer
             (NSCLC)

          -  TNM version 7 stage IV disease including M1a (malignant effusion) or M1b (distant
             metastasis), or locally advanced disease not amenable to curative treatment (including
             patients progressing after radiochemotherapy for stage III disease)

          -  Measurable or evaluable disease (according to RECIST 1.1 criteria).

          -  Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)

        Exclusion Criteria:

          -  - Patients who have had in the past 5 years any previous or concomitant malignancy
             EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ
             carcinoma of the cervix or bladder, in situ breast carcinoma.

        Patients with any known significant ophthalmologic anomaly of the ocular surface

          -  Patients who received prior chemotherapy for metastatic disease

          -  CNS metastases

          -  Patients who received previous treatment for lung cancer with drugs targeting EGFR or
             VEGF

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiyong He, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiyong He, master</last_name>
    <phone>13805086391</phone>
    <email>heyong1015@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian cancer hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyong He, master</last_name>
      <phone>0086-591-83660063</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Maemondo M, Fukuhara T, Sugawara S, et al. NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations[J]. Annals of Oncology, 2016, 27</citation>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external indepentent Review Panel. Requesdtors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

